The Fosun Pharma mRNA vaccine for COVID-19 could complete its Phase III trials in October, according to Aimin Hui, President of Global R&D at Fosun. Earlier this year, Fosun acquired China rights to the vaccine from BioNTech of Germany in a $135 million deal. Pfizer, which owns US rights to the vaccine, is conducting a Phase III trial of BNT162b2 that has already enrolled over 25,000 subjects. Fosun will stage a China bridging trial of the vaccine in China subjects and then conduct a China arm of the global Phase III trial. More details.... Stock Symbols: (SHA: 600196; HK: 2196) (NYSE: PFE) Share this with colleagues: // //